What percentage of patients receiving dasatinib (Sprycel) develop diarrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Porcentaje de Diarrea con Dasatinib

La tolerabilidad gastrointestinal de dasatinib es generalmente buena, con diarrea reportada en aproximadamente 17% de los pacientes, siendo la mayoría de grado 1-2 y raramente requiriendo interrupción del tratamiento (1-3% de los casos). 1

Incidencia Específica por Contexto Clínico

Según las guías de la European LeukemiaNet 2016, la incidencia de diarrea con dasatinib varía según el contexto:

  • Primera línea en fase crónica: 17% de incidencia total 1
  • Diarrea grado 3-4: <1% de los pacientes 1
  • Interrupción de dosis por diarrea: 1-3% de los pacientes 1
  • Reducción de dosis por diarrea: 0-2% de los pacientes 1

Comparación con Otros Inhibidores de Tirosina Quinasa

Dasatinib tiene un perfil gastrointestinal favorable comparado con otros TKIs, especialmente bosutinib que presenta diarrea en 68-81% de los casos con grados 3-4 en 8-11% 1. Esta diferencia es clínicamente significativa para la calidad de vida del paciente.

Características Temporales

  • Inicio: La mayoría de problemas gastrointestinales ocurren durante el primer mes de terapia 1
  • Duración: Generalmente autolimitada
  • Severidad: Predominantemente grados 1-2, manejables con tratamiento sintomático 1

Manejo Clínico Recomendado

Para diarrea leve a moderada:

  • Modificación dietética y tratamiento sintomático
  • No requiere ajuste de dosis si no interfiere con calidad de vida 1

Para casos más severos:

  • Medicación antidiarreica (loperamida o difenoxilato/atropina)
  • Atención a hidratación e interacciones medicamentosas
  • Aplicar reglas generales de manejo de toxicidad 1

Consideraciones Importantes

La discontinuación del tratamiento por diarrea es rara con dasatinib 1, lo que contrasta marcadamente con bosutinib donde 21% de pacientes con diarrea requieren interrupción de dosis. Esto hace de dasatinib una opción más tolerable para pacientes con preocupaciones gastrointestinales preexistentes.

La diarrea no debe considerarse una contraindicación para el uso de dasatinib, a diferencia de las enfermedades pleuro-pulmonares que sí representan contraindicaciones fuertes 2.

References

Related Questions

What is the most likely diagnosis causing endogenous hyperinsulinemic hypoglycemia in a patient with frequent CGM glucose 2.2‑3.9 mmol/L, a mixed‑meal test showing glucose 7.4 mmol/L with elevated insulin (~3500 pmol/L) and C‑peptide (~6400 pmol/L), adrenergic symptoms (heart pressure) during hypoglycemia, and no improvement with acarbose or dietary changes?
For a patient with type 2 diabetes mellitus with a specified complication who is taking metformin 1000 mg twice daily, insulin glargine (Lantus) 25 units subcutaneously twice daily, and using a Libre 2 continuous glucose monitoring system, and who stopped sitagliptin (Januvia) and glimepiride to start linagliptin (Tradjenta) 5 mg daily but cannot afford linagliptin, what cost‑effective oral medication alternatives are recommended?
In a 26‑year‑old African‑American man with obesity (BMI 36), pre‑diabetes (HbA1c ≈ 5.8‑5.9 %), mixed dyslipidemia, and stage 1 hypertension (average blood pressure 144/87 mm Hg), what non‑pharmacologic measures, single‑agent pharmacologic options, laboratory tests, and follow‑up schedule are recommended to safely lower his blood pressure to below 130/90 mm Hg within one month?
What discharge plan should be recommended for a postpartum woman, two days after delivery, with type 2 diabetes on insulin glargine (Lantus) 9 U daily without carbohydrate coverage, who is breastfeeding and currently has hyperglycemia?
What is 0.37 mmol/L of glucose expressed in mg/dL?
What is the recommended treatment for bacteremia?
What are the treatment options for hemophilia A and B (including factor VIII and IX replacement, bypassing agents, emicizumab, and gene therapy) and their associated side effects?
What is the recommended management for sciatica?
What is the first-line treatment for heartburn?
What evaluation and management is recommended for a patient with right elbow swelling one week after a fall, pain on extension, and pain radiating to the wrist?
What is the appropriate immediate management for a septic patient with uremia caused by Escherichia coli and Pseudomonas species?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question